February 28, 2019
20-22 February 2019 InSysBio company held the 12th Annual Internal Scientific Meeting. Results of the last year and plans for the ongoing year were discussed.
InSysBio launched its first consortium: Alzheimer’s Disease (AD) Modeling Consortium focused on the development of the QSP platform of AD. InSysBio completed four long-term QSP projects in collaboration with three pharmaceutical companies in areas of autoimmune, inflammatory and pulmonary diseases. The online version of Immune Response Template (IRT), a platform for QSP modeling in immunology and immuno-oncology, was launched. Two leading pharmaceutical companies became new users of IRT.
InSysBio modelers have published two research papers in PLOS One and Applied Biochemistry and Biotechnology journals, have read the course on mathematical modeling in systems biology and biomedicine in Lomonosov Moscow State University and have presented in such conferences as ASCPT 2018, PAGE 2018, AAIC 2018, ACoP 9, AAT-AD/PD Focus Meeting, ICSB 2018, Russian National Congress «Man and Drug» and BiotechClub 2018.
In 2019 along with IRT and the AD QSP platform update InSysBio is planning to publish the initial results of the developed PBPK model of antibodies, continue to develop QSP models of various therapies in immuno-oncology (CAR-T, bispecific T-cell engaging antibodies, checkpoint inhibitors) as well as develop QSP platform of hematopoiesis and drug-induced hematologic disorders. InSysBio will participate in AACR Annual Meeting 2019, 15th Annual PEGS Summit, PAGE 2019, ACoP 10 and other conferences.
About InSysBio
InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative approach has already become a part of the drug development process implemented by our strategic partners: nowadays there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. The company has published multiple scientific studies in various therapeutic areas. InSysBio team is developing software and tools for QSP and continuously improves methods for biological modeling. For more information about InSysBio, its solutions and services, visit insysbio.com.
| ← | September 2020 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
|
3
|
4
|
5
|
6
| |
|
7
|
8
|
9
1.
09 Sep 2020 14:59
InSysBio to update its Cytocon DB to version 1.2.6.7
InSysBio announces the new version of Cytocon DB 1.2.6.7! Cytocon DB team has reviewed 39 articles to implement the new data. It should be highlighted that the total number of reviewed articles within the Database has already exceeded 515!
|
10
|
11
|
12
|
13
|
|
14
|
15
|
16
1.
16 Sep 2020 14:54
InSysBio to take part in ACoP11
InSysBio announces its participation in Eleventh American Conference on Pharmacometrics (ACoP11) which is to be held in virtual format this year due to COVID-19 spread 9-13 November, 2020. The theme of ACoP11 is “Scaling New Heights.” InSysBio team is going to present 9 posters in frames of the Conference
|
17
|
18
|
19
|
20
|
|
21
|
22
|
23
1.
23 Sep 2020 10:26
InSysBio announces its collaboration with Genmab
The new partnership strives to evaluate the efficacy of a new oncology therapy – GEN1042 (DuoBody®-CD40x4-1BB)
[Moscow, Russia; Princeton, New Jersey, U.S. – 23.09.2020] InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, announces its collaboration with Genmab, an international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.
|
24
|
25
|
26
|
27
|
|
28
|
29
|
30
| ||||
Thank you for your message! We will get back to you shortly.
